ECM
CNCE

ExodusPoint Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

ExodusPoint Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,198
Closed -$109K – 2298
2022
Q3 		$109K Buy
+16,198
New +$98.2K ﹤0.01% 1736
2021
Q3 		– Sell
-12,772
Closed -$54K – 2842
2021
Q2 		$54K Buy
+12,772
New +$54.1K ﹤0.01% 2214

Other funds holding CNCE

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ExodusPoint Capital Management's CNCE Position: Q4 2022 in Review

ExodusPoint Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 16,198 shares — an estimated $109K sold.

ExodusPoint Capital Management first reported a position in CNCE in Q2 2021 and held it in 2 quarters. The position peaked at $109K in Q3 2022. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

  • ExodusPoint Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 16,198 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $109K.
  • ExodusPoint Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Concert Pharmaceuticals, Inc. position peaked at $109K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.